RxDoctor Payments Data

David Hyun, MD

Cardiovascular Disease · Santa Clara, CANPI 1255312005

Payments from drug & device makers

$6,313in general payments, 2019–2025

Across 282 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • Johnson & Johnson$838
  • Novartis$555
  • Pfizer$537
  • AstraZeneca$487
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$6,19798%
  • Education$1172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,313 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$357,089
Medicare patients
642
Services billed
1,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban267$320,277
XareltoRivaroxaban138$165,119
JardianceEmpagliflozin107$138,407
Repatha SureclickEvolocumab117$83,823
EntrestoSacubitril/Valsartan45$58,319
OzempicSemaglutide49$45,815
FarxigaDapagliflozin Propanediol46$40,593
Praluent PenAlirocumab43$24,510
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,057
MounjaroTirzepatide13$14,356
TrintellixVortioxetine Hydrobromide17$11,319
TrulicityDulaglutide13$10,773
VascepaIcosapent Ethyl15$8,020
Ezetimibe150$4,461
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide59$4,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$537$320,277267 claims
Johnson & JohnsonXarelto$838$165,119138 claims
Boehringer IngelheimJardiance$256$138,407107 claims
NovartisEntresto$555$58,31945 claims
Novo NordiskOzempic$74$45,81549 claims
AstraZenecaFarxiga$487$40,59346 claims
GSKTrelegy Ellipta$17$22,05723 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$24$11,31917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Clara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →